CurrentCapital BluecrossPolicy AHS G2149

Pathogen Panel Testing

This policy governs outpatient coverage criteria for multiplex molecular pathogen panel testing (gastrointestinal, respiratory, central nervous system, blood, urine, wound, and general screening panels) and specifies which panel sizes and specimen types meet or do not meet coverage criteria for Capital Bluecross members.

Policy Summary

PayerCapital Bluecross

PolicyPathogen Panel Testing

Policy CodePolicy AHS G2149

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionOrder multiplex panels in the outpatient setting only when clinical presentation and specimen findings indicate moderate-to-high pretest probability and document findings (e.g., CSF leukocytosis/protein or diarrhea) to support coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 11Gastrointestinal pathogens allowed per panel for coverage

6+Respiratory pathogen panel size threshold NOT covered

12+Gastrointestinal pathogen panel size threshold NOT covered

CSF panelsCerebrospinal fluid panel testing

blood panels

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Molecular blood panels

14Targets on BioFire ME panel

Coverage Criteria for Multiplex Pathogen Panels

Outpatient Multiplex Panel Coverage and Exclusions

Covered when ALL of the following are met for specified panels in the outpatient setting:

Gastrointestinal panels meeting coverage: Multiplex PCR-based panel testing for individuals with persistent diarrhea or diarrhea with signs or risk factors for severe disease (e.g., fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain) using panels up to 11 gastrointestinal pathogens meets coverage criteria no more often than once every 7 days.panel size <= 11 GIPs; frequency <= once per 7 days

Outpatient setting only

Respiratory panels meeting coverage: Multiplex PCR-based panel testing for individuals displaying signs and symptoms of a respiratory tract infection using panels up to 5 respiratory pathogens meets coverage criteria.panel size <= 5 respiratory pathogens

Outpatient setting only

Not covered gastrointestinal panels: Multiplex PCR-based panel testing of 12 or more gastrointestinal pathogens does not meet coverage criteria.

See denial_risks

Not covered respiratory panels: Multiplex PCR-based panel testing of 6 or more respiratory pathogens does not meet coverage criteria.

See denial_risks

Not covered specimen types and large panels: Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF), molecular detection-based panel testing of pathogens in blood, molecular detection-based urine panels for UTI diagnosis, wound infection panels, and general microorganism screening panels do not meet coverage criteria.

Lack of sufficient published evidence

Covered clinical indications

Covered when testing is aligned with clinical guidelines and when results are likely to impact management:

High-yield populations for multiplex panels: Use in immunocompromised hosts, acutely ill adults being considered for hospital admission, and critically ill (ICU) patients may be appropriate for multiplex respiratory or combined panels when results are likely to affect management.

Professional society joint statement

CSF/ME panel use: An FDA-cleared meningitis/encephalitis multiplex PCR panel may be used as an adjunct diagnostic tool when rapid identification would change management, recognizing variable performance for some organisms and that testing should be limited to patients with moderate-to-high pretest probability based on clinical presentation and CSF findings.

IDSA and supporting studies; order with CSF abnormalities (eg, leukocytosis or elevated protein)

Blood culture direct panels: Multiplex identification from positive blood culture bottles is appropriate to shorten time to organism and resistance gene identification and to support earlier targeted therapy when used alongside culture and susceptibility testing.

Not routinely covered / limited-use scenarios

Not covered / use not routinely recommended when:

Routine broad panels when results won't affect management: Routine ordering of broad respiratory pathogen panels or other broad multiplex panels is discouraged when the result will not change patient management.

ASCP ChoosingWisely and related guidance

Insufficient evidence for routine GI panel adoption: Routine adoption of integrated multiplex GI PCR tests for all patients with suspected gastroenteritis is not recommended due to insufficient evidence of clinical utility in general populations.

NICE 2017

Molecular tests are not replacements for culture: Multiplex molecular assays do not replace bacterial and fungal culture for susceptibility testing, epidemiology, and antibiogram/vaccine decisions; culture remains essential.

IDSA and SCCM statements

Coverage considerations and limitations

Guidance and regulatory context

Professional society guidance: Do not routinely order broad respiratory pathogen panels unless the result will affect patient management.

ASCP/ChoosingWisely (chunk 54)

Regulatory precedence: If there is a conflict between this policy and an applicable government policy (LCD/NCD or state Medicaid), the government policy controls determinations.

Applicable State and Federal Regulations (chunk 55)

LDT validation and CLIA regulation: Laboratory-developed tests must be validated and are regulated as high-complexity under CLIA; FDA clearance is not required for clinical use but validation documentation is relevant.

FDA/CLIA discussion (chunk 56)

Molecular-based panel testing for wound and skin/soft-tissue infections is not supported for routine coverage in the outpatient setting. The policy explicitly states that molecular-based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing) does not meet coverage criteria, noting that wounds are frequently colonized and that multiplex panels offered by commercial vendors vary widely in content and clinical interpretation.

Ordering multiplex PCR panels when the pretest probability is low reduces the predictive value of results and increases false positives. The policy highlights CSF testing as an example: multiplex CSF panels ordered in the absence of CSF abnormalities (for example, no leukocytosis or no elevated protein) are discouraged and should be limited to patients with a moderate-to-high clinical pretest probability of CNS infection.

Repeat gastrointestinal multiplex PCR panel testing during the same diarrheal episode is discouraged. Consistent with ACG/IDSA guidance and diagnostic studies, repeat GIP testing within seven days after an initial test is considered not medically necessary because repeat testing rarely yields a new positive result and adds no clinical value.

Routine ordering of broad respiratory pathogen panels is discouraged when results are not expected to change patient management. The ASCP/Choosing Wisely guidance cited advises clinicians to not routinely order broad respiratory panels unless the result will affect patient management, and the policy also notes that applicable government coverage (LCD/NCD or state Medicaid) takes precedence when there is a conflict.

The references section provides supporting literature and guideline citations used throughout the policy. No additional explicit exclusions are introduced in this references section.

Molecular detection–based panel testing for certain specimen types is not covered in the outpatient setting. Specifically, molecular detection–based panel testing of urine pathogens for UTI diagnosis and molecular detection–based panel testing of pathogens in blood are listed among specimen types that do not meet coverage criteria due to insufficient evidence supporting routine use.

Ordering CNS multiplex PCR panels without clinical and CSF evidence of infection diminishes test predictive value. The policy advises that CSF panel testing be ordered only when clinical presentation and CSF findings (such as elevated leukocyte count or protein) support a moderate-to-high pretest probability, because performance is variable for some targets and false positives increase when pretest probability is low.

The policy reiterates that broad respiratory panels should not be ordered routinely when results will not change management. Professional society guidance (ASCP/ChoosingWisely) discourages routine use of broad panels for respiratory illness unless findings will influence treatment or infection-control decisions, and applicable government coverage rules supersede the policy when in conflict.

This section summarizes professional-society guidance and coverage cautions related to routine use of broad respiratory panels. It does not add new not-medically-necessary statements beyond those referenced elsewhere in the policy.

The policy's references list the evidence base and guideline sources used to inform coverage recommendations. This portion of the document does not contain separate not-medically-necessary statements.

Indications Where Testing May Be Covered

Persistent diarrhea or diarrhea with signs/risk factors for severe disease

Covered when ALL of the following are met for specified outpatient gastrointestinal indications:

Indication—persistent or prolonged diarrhea: Patient has persistent diarrhea (14–30 days) or diarrhea with signs or risk factors for severe disease (for example, fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain).

Clinical definition of persistent/severe disease per policy and GI background

Test type and panel size: Multiplex PCR-based gastrointestinal panel testing using panels of up to 11 gastrointestinal pathogens meets coverage criteria.panel size <= 11 GIPs

Coverage limited to outpatient setting; frequency no more often than once every 7 days

Frequency limit: Testing will be covered no more often than once every 7 days during the same diarrheal episode.

Non-Covered Panels and Limitations

The policy designates several panel types and specimen contexts as not meeting coverage criteria in the outpatient setting. Examples include multiplex PCR-based gastrointestinal panels of 12 or more pathogens, respiratory panels of 6 or more pathogens, CSF panels, molecular blood pathogen panels, urine UTI panels, and wound infection panels. These panel types are explicitly listed as not covered due to insufficient published evidence or lack of demonstrated clinical benefit.

The policy does not support testing for organisms lacking demonstrated availability or validated performance in the clinical setting. It emphasizes that some molecular assays and laboratory-developed tests require appropriate validation and that tests for certain agents (for example, some fungal, parasitic, rickettsial, or spirochetal targets) are still in development and are not supported for routine use.

Routine adoption of integrated multiplex gastrointestinal PCR panels for all patients with suspected gastroenteritis is not supported. NICE concluded there is insufficient evidence to recommend routine adoption of integrated multiplex GI PCR tests in general populations, and the policy aligns with selective use based on demonstrated clinical utility.

Repeat PCR testing for certain pathogens is generally unnecessary. Diagnostic data and guideline recommendations indicate that repeating tests such as C. difficile PCR within short intervals rarely changes the result; therefore, repeat PCR testing after an initial negative test within a short interval is not supported and may be considered unnecessary.

The policy clarifies that routine broad respiratory panels ordered when results will not influence patient management are discouraged and may not be covered. Professional society guidance (ASCP/ChoosingWisely) recommends against routine ordering of broad respiratory panels unless the findings will affect clinical decisions, and applicable government coverage determinations take precedence where relevant.

Testing Frequency and Repeat-Testing Restrictions

Gastrointestinal multiplex PCR panel (up to 11 GIPs) — frequency limit

TestGastrointestinal multiplex PCR panel (up to 11 GIPs)

Frequency limitNo more often than once every 7 days

SettingOutpatient only

Coverage stanceMeets coverage criteria when indication met (persistent diarrhea or diarrhea with signs/risk factors for severe disease)

No frequency limits stated

ScopeNo frequency limits stated in these sections

Examples referenced

Ordering, Documentation, and Provider Responsibilities

Documentation Required

Outpatient setting and benefit verification

This policy is specific to outpatient testing; verify member benefits and any applicable government coverage (LCD/NCD/state Medicaid) at the time of the request. When there is a conflict between this policy and applicable government policy, the government policy controls the coverage determination.

Verify member benefit/coverage at time of service.
When government (Medicare/Medicaid) policy conflicts with this policy, follow the government policy (LCD/NCD/state Medicaid).

Billing Rule

Applicable procedure and PLA codes

Applicable CPT/HCPCS/PLA procedure and proprietary (PLA) codes referenced by this policy are provided for billing and claims processing. Confirm member coverage for specific codes prior to ordering.

Procedure, PLA, and Related Codes

Applicable CPT Codes (selected)CPT

87154	Culture, typing; identification of blood pathogen and resistance typing; when performed; by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
87483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen (eg, Neisseria meningitidis, Streptococcus pneumoniae, Listeria, Haemophilus influenzae, E. coli, Streptococcus agalactiae, enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus, Cryptococcus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, [description truncated in source for remaining text]).
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, 6-11 targets (description continued in source).
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, 12-25 targets (description continued in source).

Applicable PLA/HCPCS/CPT/Proprietary codes (PLA/0000U-style)mixed

87636	SARS-CoV-2 and influenza virus types A and B, multiplex amplified probe technique.
87637	Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2 and influenza A/B and respiratory syncytial virus, multiplex amplified probe technique.
0068U	Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris): amplified probe technique with qualitative report of the presence or absence of each species. Proprietary test: MycoDART-PCR.
0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH; 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility. Proprietary test: Accelerate PhenoTest BC kit.
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species; qualitative reporting of presence or absence of each species. Proprietary test: MYCODART Dual Amplification Real Time PCR Panel for 4 Aspergillus species.
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA); 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected. Proprietary test: ePlex Respiratory Pathogen Panel.
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture; amplified probe technique, each target reported as detected or not detected. Proprietary test: ePlex BCID Fungal Pathogens Panel.
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, pan gram-negative bacterial target; 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected. Proprietary test: ePlex BCID Gram-Positive Panel.
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, pan gram-positive bacterial target; 1 pan Candida target), amplified probe technique, each target reported as detected or not detected. Proprietary test: ePlex BCID Gram-Negative Panel.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected. Proprietary test: BioFire Respiratory Panel 2.1 (RP2.1).

1–10 of 26

1/3

Number of targets per code

87505Gastrointestinal pathogen multiplex — 3-5 targets

87506Gastrointestinal pathogen multiplex — 6-11 targets

87507Gastrointestinal pathogen multiplex — 12-25 targets

87631/87632/87633Respiratory virus detection codes specifying 3-5, 6-11, and 12-25 targets respectively

Billing Rule

Include the policy’s CPT/PLA codes on authorizations and claims

Refer to and use the procedure and PLA codes listed in the policy when preparing authorizations or claims for multiplex pathogen panels; ensure the billed code matches the panel target count or proprietary PLA described.

Who May Order and Clinical Preconditions

Note

Order panels only in outpatient setting; limit CSF panels to moderate‑to‑high pretest probability

This policy applies to outpatient testing and limits CSF panel orders to patients with moderate-to-high pretest probability based on clinical presentation and CSF findings (eg, CSF leukocytosis or elevated protein).

Policy is specific to outpatient testing.
CSF panels should be ordered only when clinical and CSF findings indicate moderate-to-high pretest probability.

Note

Order panels when clinical presentation and specimen findings indicate moderate‑to‑high pretest probability

Order multiplex panels only when clinical presentation and specimen findings indicate a moderate-to-high pretest probability; for CSF, correlate results with CSF leukocytosis and elevated protein to support testing.

Test when clinical presentation supports CNS infection (eg, suspected viral meningitis/encephalitis).
Correlate CSF panel use with CSF leukocytosis or elevated protein to increase predictive value.

Definitions and Test Examples

Gastrointestinal pathogen panel (GPP) / GIPs

DefinitionGastrointestinal pathogen panel (GPP/GIPs): multiplex molecular assays to detect bacterial, viral, and parasitic causes of gastroenteritis (examples: BioFire FilmArray GI Panel, Luminex xTAG)

Typical targetsPanels may include organisms such as C. difficile, E. coli, Salmonella, Shigella, norovirus, Giardia

Use caseIntended for evaluation of patients with diarrhea when testing will impact management

Respiratory pathogen panel (RPP / RP)

DefinitionRespiratory pathogen panel (RPP/RP): multiplex molecular assays that detect common viral and bacterial respiratory pathogens (examples: BioFire FilmArray RP2.1, Luminex NxTAG, QIAstat-Dx)

Typical targetsMay include influenza A/B, RSV, adenovirus, rhinovirus/enterovirus, parainfluenza, coronaviruses, Mycoplasma pneumoniae, Chlamydophila pneumoniae

Background and Evidence Summary

Multiplex PCR assays enable rapid detection of multiple pathogens from a single specimen and generally offer higher sensitivity than conventional culture or antigen-based methods. This can be especially useful when sample volume is limited (for example, CSF) or when multiple pathogens produce similar clinical syndromes. Limitations include higher cost, potential for preferential amplification leading to false negatives, inability of some molecular methods (such as 16S rRNA sequencing) to resolve strain-level features or toxin genes, and the need to interpret positive results in a clinical context because detection does not always equal causation.

Policy Summary

PayerCapital Bluecross

PolicyPathogen Panel Testing

Policy CodePolicy AHS G2149

Change TypeNo material changes

Effective Date

Next Review Date

SourceLink

On This Page

Evidence of faster time-to-result and improved antibiotic stewardship

Gastrointestinal panels—selective use: Multiplex GI panels may be used in patients with moderate-to-severe disease, dysentery, symptoms >7 days, suspected outbreaks, high-risk transmitters, or in solid organ transplant recipients to detect specific protozoal pathogens (eg, Cryptosporidium, Cyclospora, Giardia); follow ACG/IDSA guidance and avoid repeat testing within seven days.

ACG and transplant society recommendations

frequency <= once per 7 days

Repeat testing within 7 days is considered not medically necessary per IDSA guidance

Signs and symptoms of respiratory tract infection

Covered when ALL of the following are met for outpatient respiratory illness evaluation:

Clinical presentation: Patient is displaying signs and symptoms of a respiratory tract infection (upper or lower respiratory symptoms such as cough, fever, sore throat, nasal congestion, dyspnea) prompting pathogen testing.

Clinical respiratory symptoms as described in background

Test type and panel size: Multiplex PCR-based respiratory panel testing using panels of up to 5 respiratory pathogens meets coverage criteria in the outpatient setting.panel size <= 5 respiratory pathogens

Avoid routine broad respiratory panels when results will not affect management

Syndrome-specific evaluation (CNS, sepsis, diarrhea, respiratory)

Covered when testing addresses suspected infection in the relevant syndrome-specific context and when results are likely to affect management:

CNS (meningitis/encephalitis): Use CSF-targeted molecular panels when clinical presentation and CSF findings indicate moderate-to-high pretest probability for CNS infection (eg, suspected viral meningitis/encephalitis); results should be used adjunctively and interpreted alongside culture and other diagnostics.

Order with supportive CSF findings (eg, leukocytosis, elevated protein); avoid testing with low pretest probability

Bloodstream/sepsis: Use multiplex identification from positive blood cultures or sepsis panels when rapid organism and resistance information will affect antimicrobial management; panels are adjunctive to blood culture and susceptibility testing.

Studies show faster time-to-result and improved stewardship

Gastrointestinal syndrome: Use GI multiplex panels when evaluating acute infectious diarrhea in contexts such as moderate-to-severe disease, dysentery, symptoms >7 days, outbreaks, high-risk transmitters, or in solid organ transplant recipients where specific protozoa detection is required.

Follow ACG/IDSA guidance; avoid repeat testing within 7 days

Respiratory syndrome: Use respiratory panels when a respiratory pathogen result would change clinical decisions (eg, antiviral therapy, isolation) and in higher-risk populations as per society guidance.

Consider immunocompromised, acutely ill, or ICU patients

Rapid identification when results affect management (antibiotic de-escalation, isolation, targeted therapy)

Covered when rapid results will influence immediate management decisions:

Antibiotic/antifungal stewardship: Testing is covered when rapid identification of respiratory pathogens, CSF pathogens (meningitis/encephalitis), or organisms from positive blood cultures will affect antimicrobial selection, enable antibiotic de-escalation, or shorten empiric broad-spectrum therapy.

Evidence supports decreased antibiotic days and improved stewardship

Infection control and isolation: Testing is covered when prompt pathogen identification will change isolation or cohorting decisions (for example, rapid detection of influenza or other transmissible respiratory viruses).

Rapid turnaround time supports infection control actions

Targeted therapy and clinical outcomes: Testing is covered when results lead to targeted therapy that alters clinical course, reduces hospital days, or avoids unnecessary procedures.

Diagnostic studies demonstrate impact on management and outcomes

GI multiplex panels for moderate-severe diarrhea, dysentery, symptoms >7 days, outbreaks, high-risk transmitters, and SOT recipients

Covered when GI multiplex testing is likely to affect management in higher-risk or specific clinical contexts:

Indications for GI multiplex panels: Multiplex GI panels are covered for patients with moderate-to-severe diarrhea, dysentery, symptoms persisting >7 days, suspected outbreaks, high-risk transmitters, and for solid organ transplant recipients to detect protozoal pathogens such as Cryptosporidium, Cyclospora, and Giardia.

ACG and transplant society recommendations support selective use

Stool testing and C. difficile: For C. difficile evaluation, test only stools from patients with diarrhea and follow multistep institutional algorithms (eg, GDH + toxin ± NAAT arbitration); avoid repeat testing within seven days.

IDSA/CDC guidance

Detection/identification of pathogens mapped to clinical syndromes

Covered when panels are used to detect pathogens that map to the clinical syndrome under evaluation:

Respiratory, GI, CNS, bloodstream mapping: Use panels that correspond to the clinical specimen and syndrome (eg, respiratory panels for upper/lower respiratory specimens; GI panels for diarrheal stool; CSF panels for suspected meningitis/encephalitis; blood-culture-based panels for positive blood cultures).

Panel selection should match specimen and clinical syndrome

Urinary, wound, fungal panels: Testing for urinary/genitourinary infections, wound infections, and fungal infections should be limited to validated assays with demonstrated clinical utility; many urine, wound, and general screening panels do not meet coverage criteria in outpatient settings.

Certain proprietary urine and wound assays are listed but not routinely covered

Detection of pathogens across respiratory, GI, CNS, bloodstream, urinary, wound and skin/soft tissue infections

Supported by diagnostic accuracy studies, guidelines, and vendor evaluations for the listed clinical syndromes:

Evidence base for multiplex panels: Diagnostic accuracy studies, guideline recommendations (ACG, IDSA, ASCP) and vendor evaluations support use of multiplex molecular panels for respiratory, gastrointestinal, CNS, bloodstream, urinary, wound, and skin/soft tissue infections when applied to appropriate clinical indications.

References and studies cited in evidence list

Limitations and variable performance: Performance varies by pathogen and platform (eg, variable agreement for certain ME panel targets such as Cryptococcus); results should be interpreted in clinical context.

Systematic reviews and analytic studies document variable sensitivity/specificity

The references section contains the bibliographic sources used to inform the policy but does not itself list additional specific exclusion items beyond those described elsewhere in the document.

FilmArray ME panel (CSF, 14 targets); expanded BCID2 blood culture panel (43 targets)

ImplicationWhere not specified, follow clinical indications and institutional policies

GIP — repeat testing within 7 days not medically necessary

Policy statementRepeat testing of gastrointestinal pathogen panels within seven days during the same diarrheal episode is considered not medically necessary

Supporting guidanceIDSA/SHEA and ACG recommend against repeat testing within seven days and discourage routine repeat testing

Practical effectRepeat GIP within 7 days may be denied or considered not covered

No explicit frequency limits

Fragment noteNo explicit frequency limits provided in this fragment

ActionWhen absent, rely on panel-specific frequency rules elsewhere in policy or clinical guidance

Coding contextApplicable CPT/PLA codes listed in coding section; frequency not specified per code here

Frequency limits — (no content)

PlaceholderNo content provided in this fragment

NoteReferences section does not specify frequency limits here

RecommendationRefer to specific coverage and frequency entries elsewhere in policy

CPT/HCPCS examples included in policy: 87154, 87483, 87505, 87506, 87507, 87631, 87632, 87633, 87636, 87637.
PLA / Proprietary codes included: 0068U, 0086U, 0109U, 0115U and others listed in the policy. Note: this list is illustrative—use the full code list in the policy when submitting claims.

Denial Risk

Non‑covered panel types / denial triggers

The following panel types are identified in the policy as not meeting coverage criteria and are triggers for denial unless covered by an applicable government policy or individual benefit exceptions: large multiplex GI panels (12+ targets), large respiratory panels (6+ targets), CSF multiplex pathogen panels, blood pathogen panels, urine UTI panels by molecular panel, and broad wound infection panels.

Multiplex gastrointestinal panels with 12 or more pathogens — non-covered/denial trigger.
Multiplex respiratory panels with 6 or more pathogens — non-covered/denial trigger.
Multiplex CSF (CNS) pathogen panels — non-covered/denial trigger.
Molecular blood pathogen panels (sepsis panels run directly on blood) — non-covered/denial trigger.
Molecular urine UTI panels for routine UTI diagnosis (e.g., GENETWORx) — non-covered/denial trigger.
Molecular wound/skin infection panels for routine diagnosis — non-covered/denial trigger.

Documentation Required

CNS panel — pretest probability and clinical correlation

Order CSF multiplex (CNS) panels only when the patient has a moderate-to-high pretest probability of CNS infection based on clinical presentation and CSF laboratory abnormalities (for example, elevated CSF leukocyte count or elevated CSF protein). Ordering without supportive CSF findings increases false positives and reduces predictive value.

Require documented clinical signs/symptoms consistent with CNS infection (e.g., meningitis/encephalitis presentation).
Require CSF laboratory evidence supportive of infection (e.g., pleocytosis, elevated protein) to justify panel testing.

Documentation Required

Risk of over‑diagnosis with multiplex NAATs

Multiplex NAATs are highly sensitive and can detect colonization or asymptomatic carriage; interpret positive results in the clinical context to avoid over-diagnosis and unnecessary treatment.

Be aware molecular assays (including C. difficile NAATs) can be positive in asymptomatic individuals — correlate with clinical signs and symptoms.
Avoid treating based on positive multiplex results alone without clinical correlation and supporting laboratory evidence.

Note

Routine broad respiratory panels discouraged

Do not routinely order broad respiratory pathogen panels unless the result will affect patient management. Prefer targeted rapid molecular or point-of-care testing (e.g., influenza A/B, RSV) when clinically indicated.

Broad respiratory panels discouraged when results will not change management.
Use rapid molecular or point-of-care tests for influenza A/B, RSV, or Group A strep when appropriate.

Documentation Required

Clinical correlation required for CSF panel testing

Clinical correlation is required for CSF panel testing: use multiplex CSF assays as an adjunct to clinical assessment and other diagnostic methods (culture, Gram stain, serology) and recognize a negative panel does not exclude infection in all cases.

Use molecular CSF testing primarily when viral encephalitis (e.g., HSV) is suspected or when prior antibiotics reduce culture yield.
Combine molecular results with other diagnostic modalities (culture, Gram stain, serology) as needed.

Documentation Required

Document clinical and CSF findings

Document clinical presentation and CSF laboratory findings that support a moderate-to-high pretest probability for CNS infection when ordering CSF molecular panels. Insufficient documentation may lead to denial.

Record specific neurological signs/symptoms prompting testing.
Document CSF results (cell count with differential, protein, glucose) supporting infection.

Documentation Required

Stool and C. difficile documentation requirements

For stool testing and C. difficile evaluation, document that the specimen is from a patient with diarrhea and follow multistep testing algorithms (GDH + toxin EIA ± NAAT) rather than NAAT alone when institutional criteria are not pre‑specified. Repeat testing within seven days for the same diarrheal episode is discouraged.

Only test stool specimens from patients with diarrhea.
Follow recommended multistep algorithms (GDH + toxin ± NAAT) rather than NAAT alone when no institutional pre-agreed criteria exist.
Do not repeat GI pathogen panel testing within 7 days during the same diarrheal episode unless clinically justified.

Documentation Required

Regulatory and documentation considerations

When government policy applies (Medicare/Medicaid LCDs/NCDs or state Medicaid rules), that policy controls ordering and coverage determinations. Ensure documentation aligns with government requirements and submit any additional documentation requested for adjudication.

If a conflict exists between this policy and an applicable government policy, follow the government policy.
Retain and submit clinical documentation that supports medical necessity per government coverage rules when requested.

Note

Culture‑first preference for wounds

For wound and skin/soft tissue infections, culture is typically preferred; molecular testing is generally limited to a few pathogens where NAAT is specifically recommended (per IDSA).

Prefer culture-based methods for routine wound/skin infections.
Consider molecular testing (NAAT/RT-PCR) only for pathogens specifically recommended by guidelines (e.g., MRSA targets) or when culture is unlikely to be diagnostic.

CPT and PLA codes in the policy correspond to specific panel sizes and proprietary tests (e.g., 87505–87507; 87631–87633; multiple PLA 0000U-style codes).
Include the exact code matching the panel when submitting claims.

Note

Order stool/C. difficile testing only for patients with diarrhea and follow multistep algorithms

For evaluation of C. difficile, order stool testing only for patients with diarrhea and follow institutional multistep algorithms (eg, GDH + toxin with NAAT arbitration); avoid NAAT-only approaches without toxin confirmation and do not repeat testing within seven days.

Only stools from patients with diarrhea should be tested for C. difficile (ACG).
IDSA/SHEA recommend a multistep algorithm rather than NAAT alone and discourage repeat testing within seven days.

Note

Follow applicable government (LCD/NCD/Medicaid) policies for ordering and coverage

If an applicable government policy (LCD/NCD or state Medicaid) applies to the member, follow that government policy for ordering and coverage determinations.

Government policy takes precedence if it conflicts with this policy.
Consult CMS and state Medicaid resources for current coverage.

Note

No provider‑type ordering restriction specified

(This section does not specify which provider types may order tests.)

PerformanceRapid results (often within an hour) and high sensitivity/specificity for many viral targets

Central nervous system (CNS) / CSF panel

DefinitionCentral nervous system (CNS) / CSF panel: multiplex molecular assays for pathogens causing meningitis/encephalitis (example: BioFire FilmArray ME panel)

Clinical useUsed as adjunct diagnostic tool when rapid identification would change management; correlate with CSF findings

Specimen volume/exampleFilmArray ME uses 0.2 mL CSF to test multiple pathogens rapidly

BioFire FilmArray Meningitis/Encephalitis (ME) panel

TestBioFire FilmArray Meningitis/Encephalitis (ME) panel

DescriptionFDA-cleared multiplex PCR using 0.2 mL CSF to detect 14 CNS pathogens with rapid (~1 hour) turnaround

PerformanceManufacturer-stated overall sensitivity ~94.2% and specificity ~99.8%; variable sensitivity for some organisms per systematic reviews

T2Bacteria Panel

TestT2Bacteria Panel

DescriptionFDA-cleared assay that identifies certain sepsis-causing bacteria directly from whole blood without waiting for blood culture

Reported performanceReported sensitivities and coverage for common bloodstream pathogens (manufacturer-cited)

16S rRNA sequencing limitations

Limitation16S rRNA sequencing cannot resolve strain-level features such as specific toxin genes or surface antigens; some targets may be reported only to genus level

ImpactMay not distinguish pathogenic vs nonpathogenic strains (e.g., C. difficile) based on 16S alone

RecommendationInterpret results in clinical context and consider complementary methods for strain-level information

FilmArray ME panel — summary

TestFilmArray ME panel

DescriptionFDA-cleared multiplex CSF panel testing 14 pathogens from 0.2 mL CSF with rapid (~1 hour) turnaround

Performance noteVariable agreement across targets; high sensitivity and specificity for many bacteria and viruses but lower agreement for some organisms (eg, Cryptococcus in some studies)

LDT — definition

DefinitionLaboratory-developed test (LDT): an in-house test developed and validated by a laboratory; regulated as high-complexity under CLIA and requiring validation

Regulatory noteLDTs are not FDA-approved but are regulated by CMS under CLIA '88; validation documentation is required

ImplicationCoverage decisions may reference FDA-approved assays but LDTs must meet validation standards

Proprietary panels / PLA codes

MappingProprietary manufacturer panels correspond to PLA/0000U-style codes (examples listed in coding section such as BioFire, ePlex, QIAstat-Dx)

ActionUse the listed PLA/CPT/HCPCS codes when submitting claims or authorizations

ExamplesCodes and proprietary tests are enumerated in the coding section (e.g., 0202U BioFire RP2.1; 0369U GI panels)

Multiplex PCR vendor examples

ExamplesVendor systems cited include BioFire FilmArray, Luminex xTAG/NxTAG, QIAstat-Dx, Seegene, GenMark ePlex

ContextThese platforms are examples of multiplex PCR/molecular pathogen panels used for syndromic testing across respiratory, GI, CNS, and blood applications

ImplicationCoverage and performance considerations reference these commonly used commercial systems